WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today a new business alignment which unifies its Research Models and Services (RMS) and Preclinical Services (PCS) businesses. This unification will enhance our ability to provide clients with a seamless and integrated portfolio of the essential products and services required to support their drug development programs.
